

**CURRICULUM VITAE
OF
HAROLD LOGAN BROOKS, JR., M.D.
2009**

PERSONAL DATA

Private Practice Group: Southern Vitreoretinal Associates, P.L.
Feb. 1990 to present 2439 Care Drive
Tallahassee, FL 32308
(850) 942-6700

EDUCATION AND TRAINING

Pre-Medical Education: Florida Southern College
Lakeland, FL
BS Degree (Bio/Chemistry)
1972-1976

Medical School: University of Florida
Gainesville, FL
M.D. Degree
1978-1982

Internship: University of Florida
Gainesville, FL
Medical Internship
1982-1983

Residency: University of Florida
Gainesville, FL
Ophthalmology Residency
1983-1986

Board Certification: American Board Ophthalmology

Fellowship: Wills Eye Hospital
Philadelphia, PA
Retina Fellowship
1986-1988

RESEARCH AND TEACHING APPOINTMENTS

1988-1990: Vitreoretinal Foundation and Clinical Professor of Ophthalmology University of Tennessee Memphis, TN

1988-1990: Principal Investigator for the Vitreoretina Foundation/St. Jude Hospital Center in the Retinoblastoma International Collaborative Study

1988-1990: Consultant at the St. Jude Children's Research Hospital 2003

2005 to present Clinical Assistant Professor Florida State University Medical School

MEDICAL LICENSURE

1988 State of Alabama #14226

1983 State of Florida #0042558

1991 State of Georgia #036347

PROFESSIONAL ORGANIZATIONS

American Academy of Ophthalmology

American Medical Association

Christian Ophthalmologic Society

American Society of Retinal Specialists

Retina Society

ARVO

PRESENTATIONS

Rabbit Model for Epithelial Downgrowth and Treatment with 5-FU. ARVO
Sarasota, May 1986

Organic Dye Laser and the Human Fundus.
Wills Eye Conference
Philadelphia, PA 1987

Retina Society. Bermuda September 1987
University of Florida Silver Celebration
Gainesville, FL October 11, 1988

Retinal Detachment Repair and Vitrectomy for Sickle Cell Retinopathy. Wills Eye Conference
Philadelphia, PA March 1988

Retina Society. Philadelphia, PA June 1988.
First Annual Research in Vision and Ophthalmology Day
May 1989

Surgical Management of Complications of Proliferative Sickle Retinopathy without Exchange Blood Transfusion.
American Academy of Ophthalmology
New Orleans, LA October 31, 1989

Radiation Cataract Removal in Patients Treated for Retinoblastoma. American Academy of Ophthalmology
New Orleans, LA November 1, 1989

ILM Removal in Macular Hole Surgery. SE Vitreoretinal Conference
Atlanta, GA February 1995

ILM Removal in Macular Hole Surgery.
Retina Society
Washington, DC 1998

ILM in Retinal Detachment with Proliferative Vitreoretinopathy
San Francisco, CA 2002

Vitreous Levels of VEGF and SDF-1 in Patient with Diabetic Retinopathy. ARVO 2003

PRESENTATIONS (CONTINUED)

**American Academy of Ophthalmology Diabetic Workshop
2003**

**Systemic Diseases and the Eye for Optometrists in Tri-
State Area
2003 - present**

**Retinal Diseases lecture for optometrists in Tri-State Area
2003 - present**

**Brooks H.L., Caballero S., Newell, C.K., Steinmetz R.L.,
Watson D., Grant MB. "Assessment of Triamcinolone
Treatment for Neovascular Glaucoma". The ARVO Annual
Meeting Ft. Lauderdale, FL 2004**

**Endophthalmitis after 23g PPV; effect of intraocular
tamponade and sutures Logan Brooks Oct 1, 2009**

- Retrospective review of all eyes with endophthalmitis following 23g PPV over a 2 year period; all eyes categorized whether fluid-filled vs. air/gas/oil tamponade, and whether sclerotomies were sutured
- All incisions were beveled; if 1 sclerotomy was sutured, the eye was considered "sutured"
- 10 cases of endophthalmitis found in 2157 eyes (0.4%)
- 1 case in 594 sutured eyes (0.1%) developed infection
- 1 case in 762 eyes with internal tamponade developed infection (0.1%)
- 8 cases were in eyes that were fluid-filled and sutureless (0.8%)
- Over the same time period, 3 of 9671 20g cases developed endophthalmitis (0.03%)
- There is 12x decrease in infection with the use of internal tamponade, and a 7x decrease when at least 1 sclerotomy is sutured
- Recommendation: a low threshold for suturing any sclerotomies and placement of a 30% air bubble with 45° positioning overnight

CLINICAL TRIALS

Principal-Investigator:

**Miravant Study for classic subfoveal CNV, 1998-2001.
*One of the highest enrolling sites.**

Anecortave Acetate Study. Anecortave vs Visudyne therapy in patients with classic choroidal neovascularization, 2003. Principal Investigator.

ANCHOR Study. rhuFab vs Visudyne therapy for patients with age-related macular degeneration. 2003-Present. Principal Investigator.

Anecortave Acetate Prophylactic Study, 2004. Principal Investigator.

Genentech: Sailor, Anchor, Horizon (Cohort 1), Ride, Bravo, Cruise, Horizon (Cohort 2) 2006-2007.

Ophthotech Corp. A Phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovistatm (anti PDGF-B pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration. 2015.

Allergan. Safety and efficacy of Brimonidine posterior segment drug delivery system in patients with geographic atrophy secondary to age-related macular degeneration. 2015.

Alcon. A two-year, randomized, double-masked, multicenter, three arm study comparing the efficacy and safety of RTH258 versus Aflibercept in subject with neovascular age-related macular degeneration. 2015.

Roche. A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration. 2015.

CLINICAL TRIALS (continued)

Regeneron. A randomized, double-masked, active-controlled Phase II study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration. 2016.

Roche. A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema. 2016.

Regeneron. A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy. 2017.

DigiSight Technologies, Inc. The Correlation of Paxos Checkup Mobile App to Standard In Office Visual Assessment (CLEAR). 2016.

OPTHEA. Phase 2b. A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). 2018.

Clearside Biomedical. TOPAZ: a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal Anti-VEGF agent in Subjects with Retinal Vein Occlusion. 2018.

F. Hoffman-LaRoche Ltd. ARCHWAY. A Phase III, multicenter, randomized, visual-assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab in patients with Neovascular Age-Related Macular Degeneration. 2018 – 2021.

Graybug Vision, Inc. ALTISSIMO Phase IIb Long-acting IVT Sunitinib Malate Depot (GB-102) in wet AMD, 2019

CLINICAL TRIALS (continued)

Aerie Pharmaceuticals, Inc. Phase I, AR-13503 Sustained Release Intravitreal Implant in DME, 2019.

Genentech, Inc. GALLEGO Phase II, FHTR2163 in GA Secondary to AMD, 2019-2021.

Senju Pharmaceutical Co. Ltd., MT-0814 in AMD, 2020.

Kodiak Sciences Inc. BEACON Phase III, Safety of KSI-301 compared to aflibercept in Macular Edema secondary RVO, 2020-Present.

Kodiak Sciences Inc. GLIMMER Phase III, Intravitreal KS1-301 vs. Aflibercept for visual impairment secondary to treatment-naïve DME, 2020-Present.

Genetech. GALLEGOLE Open-label Extension, FHTR2163 injections for GA secondary to AMD, 2020-Present.

F. Hoffman-La Roche. COMINO Phase III, Faricimab for macular edema secondary to central retinal or hemiretinal vein occlusion, 2020-Present.

F. Hoffman-La Roche. BP41670 Phase I, R07250284 multiple ascending doses vs. port delivery in neovascular AMD, 2020-present.

F. Hoffman-La Roche. PORTAL Extension, port delivery of Ranibizumab for neovascular AMD, 2020-Present.

F. Hoffman-La Roche. BALATON, Phase III, faricimab for macular edema secondary to branch RVO, 2020-Present.

F. Hoffmann-La Roche. PAVILION Phase III, Port delivery system with ranibizumab in PDR, 2020-Present.

F. Hoffman-La Roche Ltd. PAGODA Phase III, Port Delivery System with ranibizumab in DME, 2020-Present.

Regeneron Pharmaceuticals, Inc. CANDELA Phase II, High-Dose aflibercept in wet AMD, 2020-Present.

CLINICAL TRIALS (continued)

Iveric bio. Phase III, Zimura for GA secondary to dry AMD, 2020-Present.

Gemini Therapeutics. GEM-CL-10302 Phase II, Repeat intravitreal injections of GEM103 in GA secondary AMD, 2020-Present.

NGM Biopharmaceuticals. CATALINA, Phase II. Intravitreal NGM621 for GA secondary to AMD, 2020-Present.

Hemera Biosciences. HEMERA, Phase II. AAVCAGsCD59 in DME with GA, 2021

REGENXBIO. ATMOSPHERE, Phase 2b/3. RGX-314 Gene Therapy with nAMD. 2021

Opthea. COAST, Phase 3. OPT-302 in combination with Aflibercept with nAMD. 2021

Kodiak Sciences Inc. GLOW, Phase 3. Intravitreal KSI-301 for Moderately Severe to Severe NPDR. 2021

Sub-Investigator:

Diabetic Retinopathy Clinical Research Network (DRCRnet). A pilot study of laser photocoagulation for diabetic macular edema.

Novartis MS study with Dr Ayala 2005 to present

Roche. A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration. 2016.

Genentech/Roche. A Phase III, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 (Faricimab) in Diabetic Macular Edema (YOSEMITE). 2018 - Present.

CLINICAL TRIALS (continued)

Genentech. LUCERNE, Phase III. Faricimab for wet AMD 2018.

Apellis Pharmaceuticals. DERBY Phase III, sham-controlled study of safety & efficacy of APL-2 in GA secondary to AMD. 2019-Present.

F. Hoffman-La Roche. RHONE-X Extension, faricimab in DME, 2020-Present.

Regeneron Pharmaceuticals. PULSAR Phase III, Aflibercept in neovascular AMD, 2020-Present.

Genetech. AVONELLE-X, Open-label Extension. Faricimab injections in patients with nAMD. 2021

Apellis Pharmaceuticals. GALE, Open-label Extension. Pegcetacoplan for GA secondary to AMD, 2021.

PUBLICATIONS

Brooks, H. Logan and William S. Tasman. "Diagnosis and Management of Intraocular Foreign Bodies." Current Therapy in Ophthalmic Surgery. Decker Inc., 1989.

Brooks, H. Logan and Larry E. Magargal. "Retinal Vein Obstruction." Current Therapy 3 (1989).

Brooks, H. Logan, et al. "ILM Peeling in Full Thickness Macular Hole Surgery." Vitreoretinal Surgery and Technology. 7 (1995):1-2, 8.

Brooks, H. Logan, et al. "Orbital Burkitt's Lymphoma in a Homosexual Man with AIDS." Arch Ophthalmol 102 (1984):1533-1537.

Brooks, H. Logan, et al. "More information needed regarding neovascularization and vitreous hemorrhage in branch vein occlusion." Letter to the editor. Arch Ophthalmol 105 (1987):311-312.

PUBLICATIONS (continued)

Brooks, H. Logan, et al. "Retinal Vasculitis in Crohn's Disease." AJO 103 (1987):664-668.

Brooks, H. Logan, et al. "Clinicopathologic Study of Organic Dye Laser in the Human Fundus." Ophthalmology 96 (1989):822-834.

Brooks, H. Logan, et al. "Xerophthalmia and Keratomalacia Secondary to Vitamin A Deficiency from Cystic Fibrosis." Arch Ophthalmol 108 (1990):354-357

Brooks, H. Logan, et al. "Radiation Cataract Removal in Patients Treated for Retinoblastoma." Arch Ophthalmol 108 (1990):1701-1708.

Brooks, H. Logan, et al. "Magnetic Resonance Imaging in Assessing Radioactive Plaque Placement in Treatment of Choroidal Melanoma." Therapeutic Radiology . 176 (1990):851-853.

Brooks, H. Logan, et al. "Inadvertent Globe Perforation During Retrobulbar and Peribulbar Anesthesia: Patient Characteristics, Surgical Management, and Visual Outcome." Ophthalmology 98 (1991):519-526.

Yoo HS, Brooks H. Logan, Capone A Jr., L'Herrnault NL, and Grossniklaus HE. "Ultrastructural Features of Tissue Removed During Idiopathic Macular Hole Surgery". AMI Ophthalmol 122 (1996):67-75.

Brooks, H. Logan. "Macular Hole Surgery With and Without Internal Limiting Membrane Peeling". Ophthalmology 107 (2000):1939-1948.

Steinmetz, RL, Brooks HL Jr. "Diode Laser Photocoagulation to the Ridge and Avascular Retina in Threshold Retinopathy of Prematurity." Retina. 2002 Feb;22(1):48-52.

Grossnikaus HE, Brooks HL Jr, Sippy BD, Liu P. "Retinal Translocation and Photodynamic Therapy for Age-Related Macular Degeneration with Classic Choroidal Neovascularization: A Clinopathologic Case Report." Retina. 2002 Dec;22(6)818-24.

PUBLICATIONS (continued)

Steinmetz RL, Brooks HL Jr, and Newell CK. "Management of posteriorly dislocated posterior chamber intraocular lenses with vitrectomy and pars plana removal". Retina 2004;24:556-559.

Newell CK, Steinmetz RL, Brooks HL, Jr. "Chronic Postoperative endophthalmitis caused by *Bipolaris Australiensis*". Retina

HL Brooks, Jr. MD, CK Newell MD, RL Steinmetz MD, D Watson BS, CRA, CDA, MS Segal MD, JK Harrison PhD, EW Scott PhD and MB Grant MD. "Vitreous levels of VEGF and SDF-1 in patients with diabetic retinopathy and cystoid macular edema". *Arch Ophthalmol.* 2004; 122:1801-7

Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Segal MS, Grant MB, Scott EW. " SDF-1 is both necessary and sufficient to promote proliferative retinopathy. *J Clin Invest* 2005 ;15:86-93

REFERENCES

**Melvin L. Rubin, M.D.
Professor - Dept of Ophthalmology
University of Florida College of Medicine
Gainesville, FL
(904) 392-3451**

**William S. Tasman, M.D.
Ophthalmologist-In-Chief
Wills Eye Hospital
Philadelphia, PA
(215) 928-3073**

**Jerry A. Shields, M.D.
Director of Oncology Service
Wills Eye Hospital
Philadelphia, PA
(215) 928-3105**